Evidence map›Paper›PMID 40507295›Full record

ArticleCancers2025

Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study.

Maen Abdelrahim, Abdullah Esmail, Richard D Kim, Sukeshi Patel Arora, Junaid Arshad, Ioannis A Kournoutas, Conor D O'Donnell, Todor I Totev, Amie Tan, Fan Mu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maen AbdelrahimHouston Methodist Research Institute, Houston, TX 77030, USA.
Abdullah EsmailHouston Methodist Research Institute, Houston, TX 77030, USA.ORCID 0000-0002-2337-8351
Richard D KimH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Sukeshi Patel AroraMays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0002-1176-0713
Junaid ArshadUniversity of Arizona Cancer Center, Tucson, AZ 85719, USA.ORCID 0000-0001-6576-3971
Ioannis A KournoutasMayo Clinic, Rochester, MN 55905, USA.
Conor D O'DonnellMayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0009-6291-846X
Todor I TotevAnalysis Group, Inc., Boston, MA 02199, USA.ORCID 0000-0003-0253-325X
Amie TanGenentech, South San Francisco, CA 94080, USA.
Fan MuAnalysis Group, Inc., Boston, MA 02199, USA.
Shravanthi M SeshasayeeAnalysis Group, Inc., Boston, MA 02199, USA.
Sairy HernandezGenentech, South San Francisco, CA 94080, USA.
Nguyen H TranMayo Clinic, Rochester, MN 55905, USA.

Funding

San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
Genentech, Inc., N/ANIA NIH HHS P30 AG044271
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabbevacizumabclinical effectivenesshealthcare resource utilizationhepatocellular carcinomaimmunotherapy

Identifiers

PMID40507295
PMCPMC12153728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.